NCT06620926View on ClinicalTrials.gov

Impact of IDH Mutation and Adjuvant Chemo(radio)therapy on Survival Outcome in Grade II/III Astrocytoma

CompletedOBSERVATIONAL
Enrollment

811

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

December 30, 2020

Study Completion Date

December 30, 2021

Conditions
AstrocytomaAstrocytic TumorsAstrocytoma of Brain
Interventions
OTHER

IDH mutant-type

The first arm had IDH mutant-type, then stratified according to the treatment modality they received: adjuvant chemotherapy, adjuvant radiotherapy, adjuvant chemoradiotherapy.

OTHER

IDH wild-type

The second arm had IDH mutant-type, then stratified according to the treatment modality they received: adjuvant chemotherapy, adjuvant radiotherapy, adjuvant chemoradiotherapy.

Trial Locations (1)

Unknown

Suez Canal University, Ismailia

All Listed Sponsors
lead

asmaa salama ibrahim

OTHER

NCT06620926 - Impact of IDH Mutation and Adjuvant Chemo(radio)therapy on Survival Outcome in Grade II/III Astrocytoma | Biotech Hunter | Biotech Hunter